Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Metabolism-Dependent Cytotoxicity Assay (MDCA) for the Evaluation of the DILI Potential of Drug Candidates, Upcoming Webinar Hosted by Xtalks | ||
| By: PR Newswire Association LLC. - 04 Oct 2022 | Back to overview list |
|
|
In this free webinar, learn the background and utility of novel in vitro experimental hepatic systems for evaluating drug metabolism. Attendees will learn the basis of developing the metabolism-dependent cytotoxicity assay (MDCA) and the utility of the MDCA. The featured speaker will discuss plans to develop the MDC Index for comparative analysis to known drug-induced liver injury (DILI) drugs. TORONTO , Oct. 4, 2022 /PRNewswire-PRWeb/ -- The metabolic activation and detoxification pathways of drug candidates is an important aspect of drug development. This information can be applied towards structural design to minimize toxicological liability of drug candidates, selection of animal species for preclinical evaluation of human toxicity, identification of at-risk populations based on metabolic activation and detoxification capacity and identification of environmental factors that may exacerbate drug toxicity via their induction of metabolic activating pathways and inhibition of detoxification pathways. An in vitro cytotoxicity assay can help enable this process. In this webinar, the featured speaker will review the role of metabolic activation and detoxification in drug toxicity as well as to introduce a novel in vitro experimental system, the metabolism-dependent cytotoxicity assay (MDCA) for the evaluation of the roles of drug metabolizing enzymes in drug toxicity. MDCA utilizes the cofactor-supplemented permeabilized human hepatocytes (MetMax™ Human Hepatocytes, MMHH), as an exogenous hepatic metabolic system, with human embryonic kidney 293 (HEK293) cells, a cell line deficient in xenobiotic drug metabolizing enzyme activities, as target cells for the quantification of cytotoxicity. Results with model drug-induced liver injury (DILI) drugs suggest that glutathione (GSH) attenuation of cytotoxicity may be used to identify drugs metabolized to cytotoxic reactive metabolites, a hallmark of DILI drugs. Register to learn about the novel in vitro experimental system MDCA and its role in the evaluation of cytotoxicity of drug candidates. Join Albert P. Li, PhD, Chief Scientific Officer, Pharmacology and Toxicology, Discovery Life Sciences, for the live webinar on Monday, October 17, 2022, at 11am EDT (4pm BST/UK). For more information, or to register for this event, visit Metabolism-Dependent Cytotoxicity Assay (MDCA) for the Evaluation of the DILI Potential of Drug Candidates. ABOUT XTALKS Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers. To learn more about Xtalks visit http://xtalks.com Contact:
SOURCE Xtalks 
|
||
|
||
 | Back to overview list | |